drugset / Trial / NCT04041570

Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults

NCT04041570 ↗

Non-randomizedSequentialOpen-labelPrevention

Summary

RV 508 was a Phase I, open-label, dose-escalation study to examine the safety, tolerability and immunogenicity of an investigational Ebola vaccine in healthy adults. VRC-EBOADC086-00-VP, a chimpanzee adenovirus serotype 3 vector-based Ebola vaccine, encodes wild type (WT) glycoprotein (GP) from the Sudan strain of Ebolavirus and is administered intramuscularly (IM).

Timeline

Start
2019-07-02
Primary completion
2020-09-07
Completion
2020-09-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject cAd3-EBO S Vaccine 1e+10 unknown Intramuscular
Subject cAd3-EBO S Vaccine 1e+11 unknown Intramuscular